DIN 02541009 — IMJUDO 20 MG
IMJUDO is a solution of Tremelimumab marketed by ASTRAZENECA CANADA INC. The full Tremelimumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02541009
- Brand name
- IMJUDO
- Active ingredient
- Tremelimumab
- Strength
- 20 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- ASTRAZENECA CANADA INC
- Health Canada status
- MARKETED
- Drug class
- CTLA-4 immune checkpoint inhibitor (monoclonal antibody), used in combination with a PD-L1 inhibitor
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.